secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-TECHNE Corp (TECH)
CIK:        0000842023
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001558370-24-000125
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Techne appoints Matthew McManus as President DGS; Kim Kelderman to become CEO Feb 1, 2024
--------------------------------------------------------------------------------

- Matthew McManus appointed President – Diagnostics and Genomics Segment, effective Jan 8, 2024.
- McManus receives $550K base salary, 90% target cash incentive, $950K RSU grant, and other equity awards.
- McManus succeeds Kim Kelderman, who will become Bio-Techne CEO effective Feb 1, 2024.
- Employment agreement has three-year initial term; severance equal to one year base salary plus prorated incentive.
- McManus previously led Bio-Techne's Molecular Diagnostics Division after Asuragen acquisition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/842023/000155837024000125/0001558370-24-000125-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/842023/000155837024000125/tmb-20240105x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-000125

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer